Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17060234 | 1.00 | CYP11B1 (0.43) | CYP11B1CYP11B2CYP2A6CHEK1ALDH1A1 | |
| SCHEMBL29695665 | 0.98 | CYP2A6 (0.46) | CYP11B1CYP11B2CYP2A6CHEK1ALDH1A1 | |
| SCHEMBL17060302 | 0.98 | CYP2A6 (0.46) | CYP11B1CYP11B2CYP2A6CHEK1ALDH1A1 | |
| SCHEMBL17060301 | 0.98 | CYP2A6 (0.46) | CYP11B1CYP11B2CYP2A6CHEK1ALDH1A1 | |
| SCHEMBL17060265 | 0.95 | CYP2A6 (0.46) | CYP11B1CYP11B2CYP2A6CHEK1ALDH1A1 | |
| SCHEMBL17060264 | 0.95 | CYP2A6 (0.46) | CYP11B1CYP11B2CYP2A6CHEK1ALDH1A1 | |
| SCHEMBL23812650 | 0.91 | NPY5R (0.40) | CYP11B1CYP11B2CYP2A6CHEK1ALDH1A1 | |
| SCHEMBL30808839 | 0.90 | CHEK1 (0.41) | CYP11B1CYP11B2CYP2A6CHEK1ALDH1A1 | |
| SCHEMBL30219819 | 0.90 | CHEK1 (0.41) | CYP11B1CYP11B2CYP2A6CHEK1ALDH1A1 | |
| SCHEMBL23820025 | 0.90 | CHEK1 (0.41) | CYP11B1CYP11B2CYP2A6CHEK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307410-B2 | Mcl-1 modulating compounds for cancer treatment | CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE (FR) | 2019-06-04 | — | — | US | claimed |
| EP-3114119-B1 | MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT | CENTRE DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE (FR) | 2019-05-01 | — | — | EP | claimed |
| US-20170071921-A1 | MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT | CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE (FR) | 2017-03-16 | — | — | US | claimed |
| EP-2915811-A1 | MCL-1 modulating compounds for cancer treatment | Centre Régional de Lutte contre le Cancer - Centre François Baclesse (FR) | 2015-09-09 | — | — | EP | claimed |
| US-10307410-B2 | Mcl-1 modulating compounds for cancer treatment | CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE (FR) | 2019-06-04 | — | — | US | disclosed |
| US-10307410-B2 | Mcl-1 modulating compounds for cancer treatment | CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE (FR) | 2019-06-04 | — | — | US | disclosed |
| EP-3114119-B1 | MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT | CENTRE DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE (FR) | 2019-05-01 | — | — | EP | disclosed |
| US-20170071921-A1 | MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT | CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE (FR) | 2017-03-16 | — | — | US | disclosed |
| US-20170071921-A1 | MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT | CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE (FR) | 2017-03-16 | — | — | US | disclosed |
| US-20170071921-A1 | MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT | CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE (FR) | 2017-03-16 | — | — | US | disclosed |
| EP-2915811-A1 | MCL-1 modulating compounds for cancer treatment | Centre Régional de Lutte contre le Cancer - Centre François Baclesse (FR) | 2015-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071921-A1 | MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT | MCL1, BCL2A1, BCL2L1 | CYP11B1 784/4885CYP11B2 1121/4885CYP2A6 3028/4885 |
| US-10307410-B2 | Mcl-1 modulating compounds for cancer treatment | MCL1, BCL2A1, BCL2L1 | CYP11B1 784/4885CYP11B2 1121/4885CYP2A6 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.